TRIAL DETAIL

A Phase IA, two-arm, multi-center, dose escalating study of LBH589 administered intravenously on two dose schedules in adult patients with advanced solid tumors & non-Hodgkin’s lymphoma.

Drug:
Trial Name:
A Phase IA, two-arm, multi-center, dose escalating study of LBH589 administered intravenously on two dose schedules in adult patients with advanced solid tumors & non-Hodgkin’s lymphoma.
NCT#:
Conditions:
Advanced Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date
Age of Trial (yrs)
Treatment Phase:
Gleevec-resistant
Drug Category:
HDAC inhibitor
Strategy:
Block KIT Unblock cell death genes
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
Sponsor:
Novartis
Patient Contact:
Donna Adkins
Contact email:
dadkins@nvcancer.org
Contact Phone:
(702) 822-5173
Randomized:
Randomized
IV or Oral:
IV Oral
Trial Notes:
This trial is listed in the NVCI site but is not on the list of active trials as of 12-1-08. Checked again on 5/18/09. Still not listed at NVCI.

Trial Links

 

Trial Results

 
 
 

Drug Information

Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors
 
Novartis pipeline
 
LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy
 
In the Pipeline: Panobinostat Produces Objective Responses in Advanced Hodgkin's Lymphoma
 

Trial Sites

Name
Address
City
State
Zip
Country
10441 W Twain Ave
Las Vegas
NV
89135
USA